BACKGROUND: Bullous Pemphigoid (BP) is the most common autoimmune blistering disease. Most patients are elderly and associate multiple comorbidities. Topical and systemic corticosteroids are considered as the first-line treatment for BP and immunosuppressors are used as steroid-sparing treatments but both have side effects and contraindications which are even more common in this elderly population. New treatments targeting interleukins and receptors related to BP pathogenesis have been proposed to decrease this side effects while achieving equal or better effectiveness response rates.Omalizumab is a monoclonal antibody that targets IgE that has been proposed for the treatment of BP due to the evidence that IgE autoantibodies play an essential role in BP pathogenesis. OBJECTIVES AND METHODOLOGY: To assess the efficacy and security of Omalizumab for the treatment of BP, we carried out a multicenter, retrospective, observational study including patients diagnosed of BP who received omalizumab for at least 3 months from 15 tertiary hospitals in Spain. IgE levels prior to treatment was measured and we evaluate the possible correlation with clinical response. We excluded patients treated with Omalizumab for less than 3 months as we consider this duration is insufficient for a comprehensive assessment of its efficacy. To evaluate the effectiveness of the treatment we used the percentage of BSA improvement. RESULTS: We included 36 patients. The vast majority associate multiple comorbidities and all patients had used other systemic therapies apart from corticoids before Omalizumab.83% experienced some kind of treatment response and 42% of all patient treated achieved complete response.We did not find any correlation between higher levels and a better response (p=0,1791).All patients tolerated Omalizumab without reported side-effects. CONCLUSIONS: Omalizumab is a good therapeutic alternative for BP as it obtained clinical response in most patients and nearly half of the cases achieving complete response. It showed no side effects which is crucial in elderly patients suffering from BP.
Carcinoma, Renal Cell , Kidney Neoplasms , Vasculitis, Leukocytoclastic, Cutaneous , Anilides , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/drug therapy , Humans , Kidney Neoplasms/complications , Kidney Neoplasms/drug therapy , Pyridines , Ulcer , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/pathology
Aplasia cutis congenita (ACC) associated with fetus papyraceus is a rare subtype of aplasia cutis categorized as type V in Frieden's classification. It is characterized by stellate lesions in a symmetrical distribution over the trunk and proximal extremities. Conservative treatment is recommended, but there is not a well-defined therapeutic protocol. We report the case of a type V ACC in a preterm male newborn with lesions on the trunk and scalp successfully treated with topical 1% silver sulfadiazine and petrolatum gauze with an excellent evolution. This case associates a severe affectation of the scalp which represents a rare variant of type V ACC.
Ectodermal Dysplasia , Bandages , Ectodermal Dysplasia/diagnosis , Ectodermal Dysplasia/therapy , Humans , Infant, Newborn , Male , Petrolatum , Scalp , Torso
La leishmaniasis es una infección endémica en nuestro medio. Dentro de sus presentaciones, la forma mucocutánea es la menos frecuente. A pesar de ello se ha de tener en cuenta incluso en casos clínicamente sugestivos de patología tumoral, como el que presentamos
Leishmaniasis is an endemic disease in the mediterranean region. Although mucocutaneous presentation is not frequent, we should considerate it in the differential diagnosis of tumoral pathology
Humans , Male , Middle Aged , Leishmaniasis, Cutaneous/diagnosis , Leishmania/isolation & purification , Skin Diseases, Infectious/diagnosis , Leishmaniasis, Mucocutaneous/drug therapy , Diagnosis, Differential , Lip Diseases/microbiology , Leishmaniasis, Mucocutaneous/etiology , Insect Bites and Stings/complications , Meglumine Antimoniate/therapeutic use
No disponible
Humans , Female , Infant , Mouth Mucosa/pathology , Oral Ulcer/diagnosis , Natal Teeth/abnormalities , Tongue/injuries , Oral Ulcer/pathology , Incisor
